Tamio Okimoto

895 total citations
50 papers, 643 citations indexed

About

Tamio Okimoto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tamio Okimoto has authored 50 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Tamio Okimoto's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (6 papers) and Immunotherapy and Immune Responses (4 papers). Tamio Okimoto is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (6 papers) and Immunotherapy and Immune Responses (4 papers). Tamio Okimoto collaborates with scholars based in Japan, United States and China. Tamio Okimoto's co-authors include Ryosuke Tanino, Mamoru Harada, Yukari Tsubata, Yuichi Iida, Takeshi Isobe, Hitoshi Kotani, David P. Carbone, Joseph M. Amann, Miki Imazu and Takehito Shukuya and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Tamio Okimoto

42 papers receiving 633 citations

Peers

Tamio Okimoto

PRM

ONCOL

CCM

Liyun Cao United States

Saleh Yazdani Netherlands

Su Mi China

Xu Li China

Jin‐Yu Sun China

Huiyong Chen China

Jane E. Parr United States

Ningyuan Sun China

Vahitha B. Abdul‐Salam United Kingdom

Liyun Cao United States

Tamio Okimoto

350 ×1.7

293 ×1.4

PRM

279 ×1.7

ONCOL

47 ×0.5

CCM

133 ×1.4

Citations per year, relative to Tamio Okimoto Tamio Okimoto (= 1×) peers Liyun Cao

Countries citing papers authored by Tamio Okimoto

Since Specialization

Citations

This map shows the geographic impact of Tamio Okimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamio Okimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamio Okimoto more than expected).

Fields of papers citing papers by Tamio Okimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamio Okimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamio Okimoto. The network helps show where Tamio Okimoto may publish in the future.

Co-authorship network of co-authors of Tamio Okimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Tamio Okimoto. A scholar is included among the top collaborators of Tamio Okimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamio Okimoto. Tamio Okimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanino, Ryosuke, et al.. (2025). Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR ‐Mutated NSCLC. Cancer Science. 117(2). 418–428.

Tanino, Ryosuke, et al.. (2025). Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety. Anticancer Research. 45(6). 2551–2561. 1 indexed citations

Amano, Yoshimasa, Ryosuke Tanino, Rong Sun, et al.. (2025). Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus. Anticancer Research. 45(12). 5287–5297.

Okimoto, Tamio, et al.. (2023). An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration. SHILAP Revista de lepidopterología. 11(5). e01136–e01136. 3 indexed citations

Tanino, Ryosuke, Yukari Tsubata, T Hotta, et al.. (2023). Characterization of a spontaneous mouse model of mild, accelerated aging via ECM degradation in emphysematous lungs. Scientific Reports. 13(1). 10740–10740.

Tobita, Hiroshi, et al.. (2023). Immune‐related adverse events in hepatitis treated with thiopurine‐based immunosuppressants: A case report. Thoracic Cancer. 14(13). 1208–1211. 1 indexed citations

Tsubata, Yukari, et al.. (2023). A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014. International Journal of General Medicine. Volume 16. 2125–2132.

Zhao, Bao, Anjun Ma, Jianwen Chen, et al.. (2022). SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling. Nature Immunology. 23(11). 1588–1599. 18 indexed citations

Sun, Rong, Ryosuke Tanino, Minoru Isomura, et al.. (2022). The Association Between Cyclooxygenase-2 –1195G/A (rs689466) Gene Polymorphism and the Clinicopathology of Lung Cancer in the Japanese Population: A Case-Controlled Study. Frontiers in Genetics. 13. 796444–796444. 1 indexed citations

10.

Miyawaki, Taichi, Hirotsugu Kenmotsu, Hideyuki Harada, et al.. (2021). Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer. 21(1). 1121–1121. 5 indexed citations

11.

Okimoto, Tamio, et al.. (2021). Comparative Analysis of the Attitudes toward Palliative Care between Medical Oncologists and Pulmonologists. Internal Medicine. 60(18). 2879–2885. 1 indexed citations

12.

Okimoto, Tamio, Yukari Tsubata, Ryosuke Tanino, et al.. (2021). ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent. Anticancer Research. 41(5). 2653–2660. 4 indexed citations

13.

Shukuya, Takehito, Vikas Ghai, Joseph M. Amann, et al.. (2020). Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC. Journal of Thoracic Oncology. 15(11). 1773–1781. 59 indexed citations

14.

Tanino, Ryosuke, et al.. (2019). Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Respiratory Research. 20(1). 270–270. 36 indexed citations

15.

Shukuya, Takehito, Tadaaki Yamada, Michael J. Koenig, et al.. (2019). The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(6). 1061–1076. 15 indexed citations

16.

Hotta, T, et al.. (2019). New procedure of bronchoalveolar lavage using a balloon catheter in diffuse lung diseases. Respiratory Investigation. 58(1). 68–73. 2 indexed citations

17.

Iida, Yuichi, et al.. (2018). Chloroquine augments TRAIL-induced apoptosis and induces G2/M phase arrest in human pancreatic cancer cells. PLoS ONE. 13(3). e0193990–e0193990. 28 indexed citations

18.

Tsubata, Yukari, Takeshi Honda, Tamio Okimoto, et al.. (2012). A retrospective analysis comparing the safety and efficacy of chemotherapy in elderly and non‐elderly non‐small‐cell lung cancer patients. Geriatrics and gerontology international. 12(3). 499–505. 2 indexed citations

19.

Imazu, Miki, et al.. (2005). 脈波伝播速度は心血管死亡を予想するハワイ-ロサンゼルス-広島研究からの所見. Circulation. 69(3). 259–264. 103 indexed citations

20.

Ashizawa, Kazuto, et al.. (2004). Coexistence of lung cancer and tuberculoma in the same lesion: demonstration by high resolution and contrast-enhanced dynamic CT. British Journal of Radiology. 77(923). 959–962. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact